• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Af­ter Roe, star­tups seek to fill Big Phar­ma’s male con­tra­cep­tion gap

3 years ago
Startups
In Focus

Big Phar­ma's in­creas­ing M&A en­thu­si­asm; Manchin, Schumer reach deal on drug pric­ing; Earn­ings re­caps; and more

3 years ago
Weekly

Ar­cutis pulls in a win for its top­i­cal ver­sion of an old As­traZeneca drug in plaque pso­ri­a­sis

3 years ago
Pharma
FDA+

Ab­b­Vie, No­vo Nordisk TV ads gen­er­ate most search­es in first half of 2022, ad track­er finds

3 years ago
Pharma
Marketing

CEO Pas­cal So­ri­ot says As­traZeneca is grow­ing 'new branch­es' as Covid vac­cine sales con­tin­ue to fall

3 years ago
Pharma

JA­MA study finds can­cer drug da­ta is still large­ly un­avail­able to qual­i­fied re­searchers

3 years ago
Pharma

Which drugs may be hit with ne­go­ti­a­tions if the rec­on­cil­i­a­tion bill pass­es? Wall St. an­a­lysts ex­plain

3 years ago
Pharma
Law

Ab­b­Vie stays bull­ish on fu­ture per­for­mance as Skyrizi con­tin­ues to im­press — but 'price con­trol­s' would be a game ...

3 years ago
Pharma

Trans­plant Games kick off in San Diego, rais­ing or­gan do­na­tion aware­ness, com­mu­ni­ty and hope

3 years ago
Pharma
Marketing

More dra­ma ahead: Sarep­ta plans to file for ac­cel­er­at­ed Duchenne ap­proval, with ad­comm a 'n­ear cer­tain­ty'

3 years ago
R&D

Covid-19 roundup: Mod­er­na, US sign con­tract for au­tumn boost­er dos­es; Enan­ta touts PhI re­sults for its an­tivi­ral

3 years ago
Coronavirus

Icosavax dis­cov­ers what caused its lead vac­cine to flop, and does­n't see it af­fect­ing fol­low-up pro­grams

3 years ago
R&D

Bris­tol My­er­s' com­bo hits a road­block in PhI­II kid­ney test as the search to ri­val Keytru­da con­tin­ues

3 years ago
R&D
Pharma

Af­ter near­ly a decade of work, As­traZeneca ax­es WEE1 and culls Mod­er­na-part­nered drug

3 years ago
R&D
Pharma

Seagen stays qui­et on M&A as it push­es Keytru­da-Pad­cev com­bo, con­tin­ues CEO search

3 years ago
Pharma

Ex­clu­sive: UPMC launch­es an­oth­er biotech, root­ed in the tu­mor mi­croen­vi­ron­ment

3 years ago
Financing
Startups

Tonix will test its mon­key­pox vac­cine in Kenya next year, and no eyes on ac­cel­er­at­ed path at FDA

3 years ago
R&D
Coronavirus

A new AI start­up, launched with a trio of Fred Hutch vets, wants to give a 'zoomed-in' view of can­cer cells

3 years ago
Financing
AI

Dana-Far­ber CEO Lau­rie Glim­ch­er re­signs from GSK board — is she the next NIH di­rec­tor nom­i­nee?

3 years ago
People
Pharma

For­mer eGe­n­e­sis CEO joins vTv as it tries to make a come­back; Ei­sai nabs Alzheimer’s com­mer­cial ex­ec amid lecanemab ...

3 years ago
Peer Review

By ex­ploit­ing the DNA re­pair sys­tem, Yale sci­en­tists want to crack chemother­a­py re­sis­tant brain can­cer

3 years ago
R&D

On heels of record-break­ing Q2, Pfiz­er CEO Al­bert Bourla out­lines plans to ‘go very big’ on BD

3 years ago
Pharma

UK-based Ab­b­Vie sales rep rais­es con­cerns about 's­trate­gic loi­ter­ing' out­side hos­pi­tals dur­ing the pan­dem­ic

3 years ago
Pharma

Paul Hud­son: Sanofi 'least ex­posed' to gener­ic com­pe­ti­tion as Big Phar­ma dou­bles down on Dupix­ent

3 years ago
Pharma
First page Previous page 482483484485486487488 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times